EuropaWire6d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
Joplin Globe6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...
Daily5d
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Morningstar7d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
The FDA granted Orphan Drug Designation for FASENRA for EGPA in 2018.14 Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA.
Pharmabiz21h
EU committee recommends approval of AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to ...
Yahoo Finance6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
14 Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration ... the treatment of adult patients with eosinophilic granulomatosis with polyangiitis ...
Stockhouse6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to ...
Pharmabiz6d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
ADVFN6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to ...
The Huntsville Item6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune ...
kalkinemedia6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis Sign Up/Login UK AUS NZ UK CA USA FRA GER ESP ...
BioSpace7d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
The FDA granted Orphan Drug Designation for FASENRA for EGPA in 2018. 14 Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These ...